EA
EAPIF.US Euroapi S.A
- Market cap
- USD 84.9M
- P/E
- -
- P/B
- 0.11x
- ROE
- -84.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is EAPIF.US undervalued?
Graham numberThe Graham number of Euroapi S.A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Euroapi S.A fundamental analysis
No fundamental analysis for Euroapi S.A yet.
Euroapi S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Euroapi S.A
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostag…
Full company profileEuroapi S.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Euroapi S.A annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 916M | 945M | 893M | 981M | 1.02B | 919M | 848M | 1.42B |
| Gross Profit | 87.6M | 90.5M | 109M | 177M | 165M | 142M | 139M | 223M |
| Operating Income | -500K | -10.8M | -12.8M | -800K | -234M | -120M | 200K | -34.7M |
| EBITDA | 58.1M | 71.5M | 63.5M | 120M | 71.1M | -34.7M | 141M | 335M |
| Net Income | 2.50M | -6.30M | -8.10M | -15.0M | -190M | -131M | -211M | -565M |
| EPS | 0.03 | -0.07 | -0.09 | -0.16 | -2.01 | -1.38 | -2.23 | -5.97 |
| Balance Sheet | ||||||||
| Total Assets | 1.58B | 1.60B | 1.62B | 1.74B | 1.61B | 1.49B | 1.30B | 1.24B |
| Total Liabilities | 559M | 612M | 607M | 626M | 685M | 506M | 517M | 574M |
| Shareholders' Equity | 1.02B | 989M | 1.01B | 1.11B | 928M | 984M | 788M | 668M |
| Cash & Short-term Investments | 133M | 154M | 10.3M | 79.3M | 42.9M | 73.0M | 114M | 51.9M |
| Total Debt | 64.2M | 73.4M | 24.1M | 121M | 226M | 69.1M | 65.4M | 109M |
| Cash Flow | ||||||||
| Operating Cash Flow | 34.9M | 96.8M | 71.5M | 44.8M | 5.10M | 123M | 125M | -262M |
| Capital Expenditure | 81.8M | 88.4M | 88.6M | 167M | 133M | 108M | 78.5M | 156M |
| Free Cash Flow | -46.9M | 8.40M | -17.1M | -123M | -128M | 14.9M | 47.0M | -418M |
| Ratios | ||||||||
| ROE | 0.2% | -0.6% | -0.8% | -1.4% | -20.4% | -13.3% | -26.8% | -84.6% |
| ROA | 0.2% | -0.4% | -0.5% | -0.9% | -11.8% | -8.8% | -16.2% | -45.6% |
| Net Profit Margin | 0.3% | -0.7% | -0.9% | -1.5% | -18.6% | -14.2% | -24.9% | -39.7% |
| Debt to Equity | 0.06x | 0.07x | 0.02x | 0.11x | 0.24x | 0.07x | 0.08x | 0.16x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Euroapi S.A dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | EUR 98.5M | 1.04 | - |
| 2021 | - | - | - |
| 2020 | USD 4.70M | 0.05 | - |
| 2019 | USD 6.20M | 0.07 | 248.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Euroapi S.A
- Insiders 34.84%
- Institutions 35.58%
- Public & others 29.59%
- Shares outstanding 95.5M
- Free float 50.8M
Euroapi S.A company profile
- Company name
- Euroapi S.A
- Ticker
- EAPIF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,000
- Fiscal year end
- December
- Address
- 32 rue Alexandre Dumas, Paris, France, 75011
- Phone
- 33 1 23 45 67 89
- Website
- euroapi.com
About Euroapi S.A
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; and steroids and hormones substances. It also provides API solutions, such as vitamin B12, prostaglandins, corticoids and hormones, anti-infectives, opiates and controlled substances, small and complex molecules, and intermediates and reagents. It sells their products to laboratories in the pharmaceutical industry, manufacturers of generic drug and animal health products, consumer health companies, nutrition companies, cosmetics companies, biotechnology companies, contract development and manufacturing organizations. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.
Euroapi S.A management
10- Mr. David SeignolleChief Executive Officer · born 1983
- Mr. Olivier FalutChief Financial Officer
- Mr. Jean-Francois BlancChief Operating Officer
- Sophie PalliezHead of Investor Relations
- Ms. Marion SantinChief Legal, Compliance, & IP Officer
- Ms. Raphaele HauzyChief People Officer
- Mr. Frederic LelievreChief Quality Officer
- Ms. Sylvia Cabrillac-RivesChief Strategy Officer
- Mr. Frederic RobertChief Commercial Officer
- Mr. Laurent PetitChief Research & Development Officer